翰宇药业(300199) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥76,276,447.05, a decrease of 56.27% compared to the same period last year[21] - The net profit attributable to shareholders of the listed company was -¥146,415,660.11, representing a decline of 201.52% year-on-year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥129,697,597.80, down 70.24% from the previous year[21] - The basic earnings per share were -¥0.17, a decrease of 240.00% year-on-year[21] - The diluted earnings per share were also -¥0.17, reflecting a 240.00% decline compared to the same period last year[21] - Net profit for the period was a loss of CNY 181,774,978.96, compared to a loss of CNY 148,227,434.65 in the previous year, reflecting a worsening financial performance[55] - Comprehensive income attributable to the parent company was -$177.37 million, compared to -$135.91 million in the previous year, indicating a worsening of approximately 30.67%[74] - Basic and diluted earnings per share were both -$0.20, compared to -$0.16 in the previous year, reflecting a decrease of 25%[74] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,291,433,916.81, a decrease of 8.86% from the end of the previous year[21] - The equity attributable to shareholders of the listed company was ¥1,124,420,141.14, down 11.51% compared to the end of the previous year[21] - The total assets as of September 30, 2023, were 3,291,433,916.81 yuan, down from 3,611,233,247.62 yuan at the beginning of the year[38] - The total current assets decreased to 561,410,784.10 yuan from 812,324,506.42 yuan at the beginning of the year[30] - The company’s total liabilities due within one year rose by 44.41% to CNY 662,831,708.98, primarily due to an increase in long-term borrowings[66] - Total liabilities decreased from $2.31 billion to $2.14 billion, a reduction of approximately 7.36%[72] - Owner's equity attributable to shareholders decreased from $1.27 billion to $1.12 billion, a decline of about 11.69%[72] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥54,306,793.37, a significant decrease of 780.88% year-on-year[21] - The net cash flow from operating activities for the first nine months of 2023 was -54,306,793.37 yuan, a decrease of 780.88% compared to 7,976,018.03 yuan in the same period of 2022[26] - The company reported a net cash flow from investment activities of ¥156,007,830.86, contrasting with a negative cash flow of -¥25,508,359.81 in the previous year[16] - Cash inflow from financing activities increased by 37.32% to 502,603,307.30 yuan, up from 366,002,647.16 yuan in the same period last year[26] - Cash outflow from financing activities rose by 62.80% to 653,883,387.54 yuan, compared to 401,660,571.45 yuan in the previous year[26] Expenses and Income - Total operating costs amounted to CNY 635,023,336.89, slightly up from CNY 631,773,172.05, with significant increases in sales expenses (CNY 164,916,269.68) and R&D expenses (CNY 118,110,953.63)[55] - Sales expenses decreased by 36.35% from $259.09 million to $164.92 million, primarily due to a reduction in market service fees[78] - Management expenses increased by 31.27% from $80.56 million to $105.75 million, mainly due to higher depreciation and stock incentive amortization[78] - Financial expenses rose by 39.83% from $65.59 million to $91.71 million, primarily due to increased interest expenses[78] - Other income increased by 61.20% from $17.83 million to $28.75 million, mainly due to an increase in government subsidies received[78] - The company reported a loss from investment activities of CNY 12,928,783.98, compared to a loss of CNY 810,985.95 in the previous year[55] - Investment income showed a significant decline of 1494.21%, from -$810,985.95 to -$12.93 million, primarily due to increased investment losses from the sale of stocks[78] Government Support and Product Development - The company received government subsidies amounting to CNY 4,985,510.00 during the period, contributing positively to the financial results[47] - The company received a notice of acceptance for its product Semaglutide injection from the National Medical Products Administration on September 11, 2023[36] Changes in Assets - The company's cash and cash equivalents decreased to 51,454,083.52 yuan from 106,262,995.59 yuan at the beginning of the year[30] - The inventory increased to 200,221,673.73 yuan from 189,958,503.54 yuan at the beginning of the year[30] - The company reported a 100% decrease in trading financial assets, down to CNY 0 from CNY 160,569,262.70, due to the disposal of certain stocks[66] - Investment properties increased by 40.61% to CNY 215,625,187.34, attributed to the leasing of certain properties[66] - The company reported a 193.51% increase in fair value changes, from -$57.77 million to $54.03 million, attributed to the rise in stock prices[78]